Title:Treatment with Cinacalcet in Hemodialysis Patients with Severe Secondary Hyperparathyroidism, Influences Bone Mineral Metabolism and Anemia Parameters
Volume: 15
Issue: 3
Author(s): Maria Aktsiali, Theodora Papachrysanthou , Ioannis Griveas, Christos Andriopoulos, Panagiotis Sitaras, Ioannis K. Triantafyllopoulos and George I. Lambrou*
Affiliation:
- Graduate Program “Metabolic Bones Diseases”, National and Kapodistrian University of Athens, Medical School, Mikras Asias 75, 11527, Goudi, Athens,Greece
Keywords:
Cinacalcet, renal disease, dialysis, bone mineral metabolism, anemia, hemoglobin.
Abstract: Background: Due to the premium rate of Chronic Kidney Disease, we have increased
our knowledge with respect to diagnosis and treatment of Bone Mineral Disease (BMD) in End-
Stage Renal Disease (ESRD). Currently, various treatment options are available. The medication
used for Secondary Hyper-Parathyroidism gives promising results in the regulation of Ca, P and
Parathormone levels, improving the quality of life. The aim of the present study was to investigate
the relation of cinacalcet administration to not only parathormone, Ca and P but also to anemia
parameters such as hematocrit and hemoglobin.
Materials and Methods: A retrospective observational study was conducted in a Chronic
Hemodialysis Unit. One-hundred ESRD patients were recruited for twenty-four months and were
evaluated on a monthly rate. Biochemical parameters were related to medication prescribed and the
prognostic value was estimated. Cinacalcet was administered to 43 out of 100 patients in a dose of
30-120 mg.
Results: Significant differences were observed in PTH, Ca and P levels with respect to Cinacalcet
administration. Ca levels appeared to be higher at 30mg as compared to 60mg cinacalcet.
Furthermore, a decreasing age-dependent pattern was observed with respect to cinacalcet dosage. A
positive correlation was observed between Dry Weight (DW) and cinacalcet dose. Finally, a
positive correlation between Hematocrit and Hemoglobin and cinacalcet was manifested.
Conclusions: Cinacalcet, is a potential cardiovascular and bone protective agent, which is approved
for use in ESRD patients to assist SHPT. A novel information was obtained from this study,
regarding the improvement of the control of anemia.
